Skip to main content
SpringerLink
Log in

Feasibility of Chemoradiotherapy for Oesophageal Cancer in Elderly Patients Aged ≥75 Years

A Prospective, Single-Arm Phase II Study

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background: The number of elderly patients with oesophageal cancer is expected to increase with the aging of the population and the rapidly increasing incidence of adenocarcinoma. Surgical resection is standard treatment for patients with localized disease considered fit for operation. However, elderly patients with oesophageal cancer are rarely referred for surgery.

Objective: The aim of this prospective, single-arm, phase II study was to evaluate the feasibility and efficacy (tumour response) of chemoradiotherapy in the treatment of elderly patients with localized oesophageal cancer. Secondary endpoints were progression-free survival (PFS) and quality of life (QOL).

Methods: The main study inclusion criteria were: patients aged ≥75 years; oesophageal cancer disease stage II–III; Charlson co-morbidity index score ≤4; Eastern Cooperative Oncology Group (ECOG) performance status 0–2; and weight loss <15%. The radiotherapy regimen consisted of 50 Gy over 5 weeks. Cisplatin 75mg/m2 was given on days 1 and 21 of radiotherapy. Complete response was defined as disappearance of the tumour at endoscopy and/or at oesophagography and CT scan. Written informed consent was obtained from all patients. A three-step Fleming design was used to calculate the sample size.

Results: Twenty-two patients were included in the study between March 2000 and June 2004; this sample size was sufficient to allow conclusions to be drawn from the study. The mean age of the patients was 79.4 years (range 75–89 years), 18 were male (81.8%), 15 had squamous cell carcinoma (68%) and 11 had stage IIA disease (50%). The mean Charlson co-morbidity index score was 1. All patients were compliant with the planned treatment, including doses and timing. During treatment, ECOG performance status remained stable during the first 3 weeks and worsened slightly over the last 2 weeks. Dysphagia remained stable. Five patients (22%) had transient grade 2 vomiting after the second cisplatin injection. No patient experienced nephrotoxic adverse effects and there were no toxicity-related deaths. Six weeks after treatment, 14 patients were in complete response (63.6%) and 8 patients (36.4%) had no treatment effect. The overall survival was 81.6% at 6 months and 62.4% at 1 year. The PFS at 1 year was 50%. Four patients (18.2%) were alive without disease from 2.6 to 5.5 years after treatment. In 14 evaluable patients, QOL 6 weeks after treatment was slightly altered by treatment.

Conclusions: The results of this prospective phase II study support the feasibility of chemoradiotherapy for oesophageal cancer in carefully selected elderly patients, with the potential for a curative effect.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990–94. Results and commentary. Ann Oncol 2003; 14: vl6–118

    Article  Google Scholar 

  2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003; 349: 2241–52

    Article  PubMed  CAS  Google Scholar 

  3. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Sem Radiation Oncol 2006; 17: 2–9

    Article  Google Scholar 

  4. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049–53

    Article  PubMed  CAS  Google Scholar 

  5. Bedenne L, Berdah S, Dorval S, et al. Thésaurus national de cancérologie digestive. FFCD, GERCOR, SNFGE, CLCC [online]. Available from URL: http://www.snfge.org/01-Bibliotheque/0G-Thesaurus-cancerologie/publication5/sommaire-thesaurus.asp [Accessed 2008 Jan]

  6. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593–8

    Article  PubMed  CAS  Google Scholar 

  7. Ajani JA, Walsh G, Komaki R, et al. Preoperative induction of CPT11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004; 100: 2347–54

    Article  PubMed  CAS  Google Scholar 

  8. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83

    Article  PubMed  CAS  Google Scholar 

  9. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1999; 337: 161–7

    Article  Google Scholar 

  10. Ogilvie AL, Dronfield MW, Ferguson R, et al. Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. Gut 1982; 23: 1060–7

    Article  PubMed  CAS  Google Scholar 

  11. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS, 2003 Mar 31 [online]. Available from URL: http://ctep.cancer.gov [Accessed 2006 Aug 9]

  12. ICRU Report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU Report 50). Bethesda (MD): ICRU, 1999 Nov 1

  13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76

    Article  PubMed  CAS  Google Scholar 

  14. Blazeby JM, Alderson D, Winstone K, et al. Development of a EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. Eur J Cancer 1996; 32: 1912–7

    Article  Google Scholar 

  15. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143–51

    Article  PubMed  CAS  Google Scholar 

  16. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144–53

    Article  PubMed  CAS  Google Scholar 

  17. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of Standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck. J Clinic Oncol 2003; 21: 92–8

    Article  Google Scholar 

  18. Forastiere A, Koch W, Trotti A, et al. Head and neck cancer. N Engl J Med 2001; 345: 1890–900

    Article  PubMed  CAS  Google Scholar 

  19. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (RTOG 94-05) phase III trial of combined-modality therapy for esophageal cancer: high dose versus standard dose radiation therapy. J Clin Oncol 2002; 20: 1167–74

    Article  PubMed  CAS  Google Scholar 

  20. Calais G, Dorval E, Louisot P, et al. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for stages IIB and III esophageal carcinoma: results of a pilot study. Int J Radiat Oncol Biol Phys 1997; 38: 769–75

    Article  PubMed  CAS  Google Scholar 

  21. Yorozu A, Dokiya T, Oki Y, et al. Curative radiotherapy with high dose rate brachytherapy boost for localized esophageal carcinoma: dose effect relationship of brachytherapy with the balloon type applicator system. Radiother Oncol 1999; 51: 133–9

    Article  PubMed  CAS  Google Scholar 

  22. Gaspar LA, Winter K, Kocha WI, et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (RTOG study 9207). Cancer 2000; 88: 988–95

    Article  PubMed  CAS  Google Scholar 

  23. Conroy T, Yataghene Y, Etienne PL, et al. Definitive chemoradiotherapy with Folfox 4 or 5FU-cisplatin as first line treatment for patients with inoperable esophageal cancer: final results of a randomized phase II study [abstract no. 4532]. ASCO Gastrointestinal Cancers Symposium; 2007 Jan 19–21; Orlando (FL)

  24. Gibson MK, Abraham SC, Wu TT. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003; 9: 6461–68

    PubMed  CAS  Google Scholar 

  25. Wilkinson NW, Black JD, Roukhadze E, et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 2004; 8: 448–53

    Article  PubMed  Google Scholar 

  26. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567–78

    Article  PubMed  CAS  Google Scholar 

  27. Anderson SE, Minsky BD, Bains M, et al. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer 2007; 96: 1823–7

    Article  PubMed  CAS  Google Scholar 

  28. Ruol A, Portale G, Castoro G, et al. Management of esophageal cancer in patients aged over 80 years. Eur J Cardiothorac Surg 2007; 32: 445–8

    Article  PubMed  Google Scholar 

  29. Alexiou C, Beggs D, Salama FD, et al. Surgery for oesophageal cancer in elderly patients: the view from Nottingham. J Thorac Cardiovasc Surg 1998; 116: 545–53

    Article  PubMed  CAS  Google Scholar 

  30. Keeling P, Gillen P, Hennessy TP. Oesophageal resection in the elderly. Ann R Coll Surg Engl 1998; 70: 34–7

    Google Scholar 

  31. Poon RT, Law SY, Chu KM, et al. Esophagectomy for carcinoma of oesophagus in the elderly: result of current surgical management. Ann Surg 1998; 227: 357–64

    Article  PubMed  CAS  Google Scholar 

  32. Bonavina L, Incarbone R, Saino G, et al. Clinical outcome and survival after esophagectomy for carcinoma in elderly patients. Dis Esophagus 2003; 16: 90–3

    Article  PubMed  CAS  Google Scholar 

  33. Moskovitz AH, Rizk NP, Venkatraman E, et al. Mortality increases for octogenarians undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2006; 82: 2031–6

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Radiation Therapy, Besançon University Hospital, 2, Boulevard Fleming, 25030, Besançon Cedex, France

    Stephanie Servagi-Vernat, Mathieu Bosset, Jöelle Buffet-Miny & Jean François Bosset

  2. Department of Radiation Therapy, Centre Georges François Leclerc, Dijon, France

    Gilles Crehange & Philippe Maingon

  3. Department of Biostatistics, Besançon University Hospital, Besançon, France

    Marc Puyraveau & Mariette Mercier

Authors
  1. Stephanie Servagi-Vernat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathieu Bosset
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gilles Crehange
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jöelle Buffet-Miny
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marc Puyraveau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Philippe Maingon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mariette Mercier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jean François Bosset
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephanie Servagi-Vernat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Servagi-Vernat, S., Bosset, M., Crehange, G. et al. Feasibility of Chemoradiotherapy for Oesophageal Cancer in Elderly Patients Aged ≥75 Years. Drugs Aging 26, 255–262 (2009). https://doi.org/10.2165/00002512-200926030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200926030-00006

Keywords

Search

Navigation